Get the Stockscreener App
17.32
0.70%
0.12
After Hours:
17.32
Novocure Ltd stock is traded at $17.32, with a volume of 1.68M.
It is up +0.70% in the last 24 hours and up +0.93% over the past month.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
See More
Previous Close:
$17.20
Open:
$17
24h Volume:
1.68M
Relative Volume:
1.07
Market Cap:
$2.01B
Revenue:
$674.41M
Net Income/Loss:
$-173.05M
P/E Ratio:
-11.29
EPS:
-1.5343
Net Cash Flow:
$-48.07M
1W Performance:
+11.89%
1M Performance:
+0.93%
6M Performance:
+21.20%
1Y Performance:
-2.20%
1-Day Range:
$16.80
$17.80
1-Week Range:
$14.96
$17.80
52-Week Range:
$9.82
$18.92
Novocure Ltd Stock (NVCR) Company Profile
Name
Novocure Ltd
Sector
Industry
Phone
44 (0)15 3475 6700
Address
NO. 4 THE FORUM, ST. HELIER
Compare NVCR vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
17.32 | 1.75B | 674.41M | -173.05M | -48.07M | -1.5343 |
ABT
Abbott Laboratories
|
95.63 | 158.05B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
324.73 | 120.70B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.06 | 100.14B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.60 | 63.44B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
95.18 | 52.09B | 6.30B | 1.07B | 1.09B | 1.8406 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jul-08-25 | Initiated | Ladenburg Thalmann | Buy |
| Dec-02-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-16-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Aug-28-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-08-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-04-23 | Initiated | SVB Securities | Outperform |
| Jul-31-23 | Upgrade | Evercore ISI | Underperform → In-line |
| Jun-07-23 | Upgrade | Wedbush | Underperform → Neutral |
| May-16-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-17-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-06-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-05-23 | Reiterated | H.C. Wainwright | Buy |
| Nov-29-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-24-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-05-22 | Downgrade | Evercore ISI | In-line → Underperform |
| May-16-22 | Initiated | H.C. Wainwright | Buy |
| Feb-08-22 | Initiated | Loop Capital | Buy |
| Feb-02-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-20-22 | Upgrade | Truist | Hold → Buy |
| Jan-03-22 | Upgrade | Evercore ISI | Underperform → In-line |
| Jul-01-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-14-21 | Downgrade | Wedbush | Neutral → Underperform |
| Jan-25-21 | Reiterated | Piper Sandler | Overweight |
| Sep-23-20 | Initiated | Northland Capital | Outperform |
| Sep-18-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-17-20 | Downgrade | Truist | Buy → Hold |
| Jun-01-20 | Resumed | Oppenheimer | Perform |
| May-01-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-09-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Mar-05-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-29-19 | Upgrade | SunTrust | Hold → Buy |
| Jul-26-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-26-19 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-20-19 | Initiated | SunTrust | Hold |
| Nov-02-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Jul-16-18 | Initiated | Evercore ISI | Outperform |
| Apr-18-18 | Reiterated | Mizuho | Buy |
| Feb-23-18 | Reiterated | Mizuho | Buy |
| May-24-17 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Jul-29-16 | Reiterated | Wedbush | Outperform |
| Jan-19-16 | Initiated | Barclays | Underweight |
| Dec-02-15 | Initiated | Deutsche Bank | Hold |
View All
Novocure Ltd Stock (NVCR) Latest News
NVCRNovoCure Ltd Volatility & Greeks - Finviz
NovoCure (NVCR) CHRO acquires 1,905 discounted shares in ESPP purchase - Stock Titan
NovoCure (NVCR) CEO adds 1,905 shares through 2025 employee share purchase plan - Stock Titan
NovoCure (NVCR) General Counsel adds 1,299 ESPP shares to holdings - Stock Titan
NovoCure (NASDAQ: NVCR) director adds shares through 2025 employee stock purchase plan - Stock Titan
Novocure sets July 23 call for Q2 2026 results before markets open - Stock Titan
HeartFlow vs. NovoCure: Which Emerging Healthcare Stock Is a Better Buy in 2026? - AOL.com
symbol__ Stock Quote Price and Forecast - CNN
Novocure's Optune Pax Receives EU CE Mark for Pancreatic Cancer Treatment - GuruFocus
Novocure wins CE Mark for Optune Pax pancreatic cancer treatment - grafa.com
Novocure (NVCR) Gains CE Mark for New Pancreatic Cancer Treatmen - GuruFocus
Novocure receives CE Mark for pancreatic cancer device in Europe By Investing.com - Investing.com Nigeria
Novocure’s Optune Pax® Wins CE Mark for Pancreatic Cancer After Phase 3 Success in PANOVA-3 Trial - Minichart
Novocure receives CE Mark for pancreatic cancer device in Europe - Investing.com
Optune Pax CE Mark expands Novocure (NASDAQ: NVCR) pancreatic cancer reach - Stock Titan
Wearable pancreatic cancer device Optune Pax wins CE Mark in Europe - Stock Titan
NovoCure (NVCR) Is Up 8.1% After TRIDENT Shows No Survival Gain From Earlier TTFields Start - Sahm
NovoCure Ltd. Shs Unsponsored Brazilian Depositary Receipt Repr 0.1 Sh - TradingView
NovoCure (NVCR) Could Be 42% Undervalued On Mixed TRIDENT Trial Results - simplywall.st
NovoCure Ltd. Actuals & Estimates (NASDAQ:NVCR) - TradingView
NovoCure Ltd. Actuals & Estimates (LSX:A140ML) - TradingView
NVCR Forecast — Price Target — Prediction for 2027 - TradingView
2026-06-23 | Bronstein, Gewirtz & Grossman, LLC Encourages NovoCure Limited (NVCR) Investors to Inquire about Securities Investigation | NDAQ:NVCR | Press Release - Stockhouse
H.C. Wainwright Maintains Novocure(NVCR.US) With Buy Rating, Maintains Target Price $46 - Moomoo
NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026? - Yahoo Finance
NovoCure StockSunday background on TTFields cancer therapy specialist - AD HOC NEWS
NovoCure (NVCR) Is Down 19.7% After TRIDENT Misses Survival Endpoint In Earlier TTFields Use - simplywall.st
NovoCure (NVCR) Stock Could Be 31.5% Undervalued After TRIDENT Trial Result - Sahm
Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026? - Yahoo Finance
FreeCast surges premarket; Accenture, Novocure slide By Investing.com - Investing.com Canada
Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR) - Moomoo
Novocure (NVCR) Experiences Significant Decline in Stock Price - GuruFocus
NVCR Reiterated by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
Novocure’s Optune Gio fails to show benefit at earlier stage - Yahoo Finance
Novocure TRIDENT trial misses primary endpoint - grafa.com
H.C. Wainwright Maintains Novocure(NVCR.US) With Buy Rating, Cuts Target Price to $46 - Moomoo
Novocure (NVCR) Reports TRIDENT Trial Results for Glioblastoma T - GuruFocus
Novocure Announces Topline Phase 3 TRIDENT Trial Data for TTFields Therapy in Newly Diagnosed Glioblastoma Patients – Minichart - Minichart
Novocure (NVCR) Faces 20% Drop After Phase 3 Trial Setback - GuruFocus
Novocure (NVCR) Sees Significant Decline in Stock Price - GuruFocus
Novocure Brain Cancer Study Shows No Significant Survival Benefit, Stock Tanks - Benzinga
Novocure Shares Slide After Phase 3 Glioblastoma Study Falls Short of Survival Goal - Yahoo Finance
Novocure device fails to improve brain cancer patients’ survival in phase 3 test - Fierce Biotech
Novocure Ltd (NVCR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Novocure stock tumbles after trial misses primary endpoint By Investing.com - Investing.com Australia
Why is Novocure stock plummeting today? By Investing.com - Investing.com Australia
FreeCast surges premarket; Accenture, Novocure slide - Investing.com
Novocure’s glioblastoma trial fails primary endpoint - Investing.com
Novocure’s glioblastoma trial fails primary endpoint By Investing.com - Investing.com Australia
Novocure Ltd Stock (NVCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.62%
2.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):